[1] 张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析. 实用肝脏病杂志, 2019, 22(5):736-739. [2] Liu Z, Yi L, Chen J, et al. Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma. BMC Med Imaging, 2020, 20(1):71-79. [3] Zhai LL, Ju TF, Zhou CH, et al. Spontaneous rupture of giant hepatic hemangioma: misdiagnosis as gastrointestinal perforation. J Int Med Res, 2019, 47(9):4514-4521. [4] Du SF, Wang XL, Ye CL,et al. Exercise training ameliorates bleomycin-induced epithelial mesenchymal transition and lung fibrosis through restoration of H2S synthesis. Acta Physiol (Oxf), 2019, 225(2):13177. [5] 贾科峰, 于长路, 孙诚, 等. 乏血供型肝血管瘤的介入治疗疗效分析及治疗模式探讨. 中华消化杂志, 2018, 38(12):835. [6] 国际肝胆胰协会中国分会肝血管瘤专业委员会. 肝血管瘤诊断和治疗多学科专家共识(2019版). 中华消化外科杂志, 2019, 18(8):705-710. [7] 袁冰, 张金龙, 袁凯, 等. 应用博来霉素行超选择性肝动脉栓塞术治疗肝血管瘤. 中华肝胆外科杂志, 2018, 24(8):510-513. [8] Campbell V, Beckett R, Abid N, et al. Resolution of consumptive hypothyroidism secondary to infantile hepatic hemangiomatosis with combination propranolol and levothyroxine. J Clin Res Pediatr Endocrinol, 2018, 10(3):294-298. [9] Igarashi G, Mikami K, Sawada N, et al. Interventional treatment for giant hepatic hemangioma accompanied by arterio-portal shunt with ascites. Intern Med, 2018, 57(19):17-21. [10] Dong W, Qiu B, Xu H, et al. Invasive management of symptomatic hepatic hemangioma. Eur J Gastroenterol Hepatol, 2019, 31(9):1079-1084. [11] Lan Y, Li X, Liu Y, et al. Pingyangmycin inhibits glycosaminoglycan sulphation in both cancer cells and tumour tissues. J Cell Mol Med, 2020, 24(6):3419-3430. [12] Peart J. Lipiodol visibility under ultrasound in a model pelvis - assumptions about fallopian tube calibre may be misleading. Aust N Z J Obstet Gynaecol, 2020, 60(5):12-13. [13] Xu M, Pan E, Wang W, et al. The value of clinical and ultrasound features for the diagnosis of infantile hepatic hemangioma: comparison with contrast-enhanced CT/MRI. Clin Imaging, 2018, 51(1):311-317. [14] Wang K, Zhang T, Lei Y, et al. Identification of ANXA2 (annexin A2) as a specific bleomycin target to induce pulmonary fibrosis by impeding TFEB-mediated autophagic flux. Autophagy, 2018, 14(2):269-282. [15] Persson IM, Hkansson HF, Rbom A, et al. Imaging biomarkers and pathobiological profiling in a rat model of drug-Induced interstitial lung disease induced by bleomycin. Front Physiol, 2020, 11(6):584-602. [16] Liu Y, Han J, Pan H, et al. Oral delivery of pingyangmycin by layer-by-layer (LbL) self-assembly polyelectrolyte-grafted nano graphene oxide. J Nanosci Nanotechnol, 2019, 19(4):2260-2268. [17] Schniering J, Benešová M, Brunner M, et al. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. Ann Rheum Dis, 2019, 78(2):218-221. [18] Wang Z, Tang X, Qi X, et al. Feasibility, safety, and efficacy of ultrasound-guided percutaneous microwave ablation for giant hepatic hemangioma. Int J Hyperthermia, 2018, 35(1):246-252. [19] Zhu Z, Cai P, Zhu J, et al. Neonatal giant hepatic hemangioma: a case report. Medicine, 2018, 97(42):12863. [20] Wang S, Yang M, Yang X, et al. Endothelial pyroptosis underlies systemic inflammatory response following radiofrequency ablation of hepatic hemangiomas. Scand J Clin and Lab Inv, 2019, 79(39):619-628. [21] Hwang JA, Kang TW, Cha DI, et al. Differentiation of hepatic sclerosed hemangiomas from cavernous hemangiomas based on gadoxetic acid-enhanced magnetic resonance imaging features. J Comput Assist Tomogr, 2019, 43(5):762-769. |